Development Of Hepatitis B Surface Antigen As A Generic Vector For The Delivery Of Foreign CTL Epitopes.
Funder
National Health and Medical Research Council
Funding Amount
$439,642.00
Summary
Many kinds of cancer and infections display unique proteins which the body's immune system can recognise as ' foreign', and mount an immune response which, if correctly harnessed, will kill the cancer or infected cells . A way to harness the immune response is to vaccinate with these unique proteins. However, new ways need to be found to deliver the unique proteins to produce the maximal possible anti- cancer or pathogen response, and one that is long lived. In particular one needs to stimulate ....Many kinds of cancer and infections display unique proteins which the body's immune system can recognise as ' foreign', and mount an immune response which, if correctly harnessed, will kill the cancer or infected cells . A way to harness the immune response is to vaccinate with these unique proteins. However, new ways need to be found to deliver the unique proteins to produce the maximal possible anti- cancer or pathogen response, and one that is long lived. In particular one needs to stimulate the cellular arm of the immune response to produce killer cells named CTLs which specifically kill cancer or infected cells. In this project we plan to use an already-licensed human vaccine - the Hepatitis B surface antigen vaccine , or HBsAG, - and genetically modify it to contain important regions of cancer or pathogen proteins termed 'epitopes'. We surmise that immunisation with these modified HBsAg will elicit powerful CTL responses which will killer cancer or infected cells.Read moreRead less
T-follicular Helper Cell Subtypes That Induce Protective Anti-malaria Antibodies
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
Malaria causes significant disease burden globally. Currently there are no malarial vaccines that are suitable for widespread use. The development of effective vaccines is hampered by limited understanding of how the human immune system fights malaria. This project will use human samples collected to investigate how human blood cells activate the immune system to fight malaria. This research will identify avenues to improve the design of malaria vaccines in the future.
Characterization Of H. Pylori –specific CD4 T Cell Responses And The Evaluation Of The Basic Requirements For The Development Of An Effective Anti-H. Pylori Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$313,161.00
Summary
H. pylori infect over half of the global population. Although infection results in asymptomatic gastritis in most cases 10 % develop gastric ulcers and cancer. Current vaccination strategies have failed to protect humans from infection. We aim to characterise the main immune cells involved in H. pylori infection, specifically the bacteria-specific CD4 T cells. We will then try to understand the basic requirements for a successful vaccine in order to develop new, improved anti-H. pylori vaccines.
HIV is one of the highest public health priorities of our time. Traditional vaccines have been unsuccessful highlighting the need for alternative approaches to HIV vaccine design. We propose to modify a novel technology developed initially for targeted drug delivery, termed “capsules”, for the purpose of inducing an immune response. This is a generic technology with applications for other infectious diseases and cancer and brings together disparate disciplines of nanochemistry and immunology.
Immunopathogenesis And Manipulation Of The HIV Reservoir
Funder
National Health and Medical Research Council
Funding Amount
$494,732.00
Summary
Kelleher is a Clinical immunologist with a globally recognised, sustained track record of translational research which has impacted both on our understanding of HIV immunopathogenesis and on the way HIV infection is treated. He will conduct a series of studies that encompass basic scientific techniques through to pivotal pre-clinical and clinical studies that will provide a pathway towards control of HIV-infection without daily therapy.
IL-2-anti-IL-2 Complexes In Immunity To Blood Stage Malaria Infection And Prevention Of Cerebral Immunopathology
Funder
National Health and Medical Research Council
Funding Amount
$586,428.00
Summary
Cerebral malaria is a severe complication of malaria infection, which accounts for a large proportion of malaria-related deaths each year. There is no vaccine against malaria licensed for use in humans. Trial vaccines have been shown to protect poorly against cerebral malaria, and have on occasion, increased the its incidence amongst experimental animals. We aim to develop a safe malaria vaccine that controls malaria parasite numbers in the body, and also prevents cerebral malaria.
Human Dendritic Cell Subsets And Their Application For Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Immunotherapy is a promising non-toxic strategy for the treatment of many cancers, viruses and other diseases. It works by teaching the patient's own immune system to recognize and destroy the cancer. Specialized blood cells called dendritic cells are essential to this process but they are poorly understood in humans. I aim to investigate the function these cells and use this information to develop new treatments for cancer and viruses.
Systematically Exploring The Contribution Of Immunoproteasome To Immunodominance And T Cell Function
Funder
National Health and Medical Research Council
Funding Amount
$499,860.00
Summary
Vaccine will help us to fight both infectious diseases and malignancy. However, there are few successful vaccines for infectious agents and there is simply no vaccine to cure any tumor at the moment. So, it is essential for us to learn the basics related to vaccine development. Killer T cells eliminate tumour cells or virally infected host cells by recognising fragments (epitopes) derived from tumour- or virus-derived proteins displayed on a host molecule called MHC. Normally multiple epitopes a ....Vaccine will help us to fight both infectious diseases and malignancy. However, there are few successful vaccines for infectious agents and there is simply no vaccine to cure any tumor at the moment. So, it is essential for us to learn the basics related to vaccine development. Killer T cells eliminate tumour cells or virally infected host cells by recognising fragments (epitopes) derived from tumour- or virus-derived proteins displayed on a host molecule called MHC. Normally multiple epitopes are generated as part of the protein recycling program referred as proteine degradation which is mainly conducted by bundled enzyme complex, called proteasome. Two major forms of proteasomes are expressed by most cells. One called house-keeping proteasome and the other, which replaces the house-keeping one during viral infections is called immunoproteasome. The role that the immunoproteasome plays during anti-viral and anti-tumoral immune responses is not fully understood. In addition, the immunoproteasome is also expressed by a few cell types that do not suppose to need it if its function is entirely to generate better epitopes for MHC to display. In this project, we will sytematically explore the contribution of the immunoproteasome to overall anti-viral and anti-tumoral immune responses in three mouse model systems. The shared feature of these systems is that multiple killer T cell epitopes have been defined, which could potentially provide us with very sensitive assessments. The three systems are anti-influenza, anti-vaccinia virus and anti-tumor antigen (NY-ESO-1) mouse models.Read moreRead less
My research is aiming to study how the immune system controls viral infections in transplant patients and use this information to bolster their immunity in a test tube, providing protection against a virus the patient is unable to fight after their transplant. We are also trying to develop new strategies to use patient's own blood cells which will be grown in the laboratory and returned to the patient, resulting in a full recovery.
A Novel Vaccine Formaultion To Prevent Birth Defects
Funder
National Health and Medical Research Council
Funding Amount
$530,922.00
Summary
Congenital cytomegalovirus (CMV) infection is one of the TORCH infections (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex) and is one of major cause of birth defects. Transmission of CMV infection from mother to unborn babies can lead to deafness, blindness, small head syndrome (microcephaly), seizures and mental retardation. There is an urgent need to develop an effective vaccine against CMV. This project is aiming to develop a novel CMV vaccine formulation for clinical testing in ....Congenital cytomegalovirus (CMV) infection is one of the TORCH infections (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex) and is one of major cause of birth defects. Transmission of CMV infection from mother to unborn babies can lead to deafness, blindness, small head syndrome (microcephaly), seizures and mental retardation. There is an urgent need to develop an effective vaccine against CMV. This project is aiming to develop a novel CMV vaccine formulation for clinical testing in humans.Read moreRead less